Oncology - European Medical Journal

Continue

Oncology

Filter
20 Apr 2018

New Discovery Could Help Overcome Chemoresistance in a Form of Breast Cancer

Improved care for triple-negative breast cancer (TNBC) could take place following the discovery that the condition is chemoresistant even before…
19 Apr 2018

Engineered T Cells Shown to Eliminate Paediatric Brain Cancer

Elimination of a paediatric brain tumour called diffuse intrinsic pontine glioma (DIPG) has successfully taken place in a mouse model through the…
17 Apr 2018

Trial Results Lead to Calls for all Advanced NSCLC Patients to Receive Immunotherapy

All patients with advanced non-small-cell lung cancer (NSCLC) should receive immunotherapy according to Prof Solange Peters, ESMO President Elect…
12 Apr 2018

Cancer Genetic Mutations Not All Treatable: System to Rank Relevance of Mutations Needed

ESMO, the leading professional organisation for medical oncology, welcomes the latest reports from The Cancer Genome Atlas (TCGA) as a major…
6 Apr 2018

Discovery of Mutations that are Functional in Cancer Could Provide New Treatment Targets

Potential new targets for cancer treatments have been identified following the discovery of nearly 200 mutations in non-coding DNA that have a functional…
21 Mar 2018

Synthetic Enzymes Can Deliver Drugs in Cells

Drugs could be activated in biological environments such as living cells by Single-Chain Polymeric Nanoparticles (SCPN) mimicking enzymes, according to…
21 Mar 2018

Agendia Announces CE Mark for NGS-Based MammaPrint® BluePrint® Kit Enhancing Access to Personalized Treatment for Breast Cancer Patients in Europe

Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its next-generation sequencing (NGS)-based…
14 Mar 2018

New Understanding of Microtubule Railway System Could Lead to Improved Cancer Treatments

New research has shown how microtubule rails inside cells can optimise their structure to improve their efficiency and productivity, according to…
We’ve noticed you’re accessing
from North/South America.